REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Abstract

In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group. (Funded by Regeneron Pharmaceuticals and the Biomedical and Advanced Research and Development Authority of the Department of Health and Human Services; ClinicalTrials.gov number, NCT04425629.).

Keywords

Coronavirus disease 2019 (COVID-19)VirologyNeutralizing antibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakAntibodyMedicineImmunologyVirusOutbreakInternal medicineInfectious disease (medical specialty)

MeSH Terms

AdultAntibodiesMonoclonalHumanizedAntibodiesNeutralizingCOVID-19Double-Blind MethodDrug CombinationsFemaleHumansImmunologic FactorsLeast-Squares AnalysisMaleMiddle AgedOutpatientsReverse Transcriptase Polymerase Chain ReactionSARS-CoV-2Viral LoadCOVID-19 Drug Treatment

Affiliated Institutions

Related Publications

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre‐Xabier , Nita Patel , Jing-Hui Tian +10 more

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective effi...

2020 Vaccine 238 citations

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu Bennet , Jayanthi Wolf , Rodrigo Laureano +1 more

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...

2020 Toxicologic Pathology 47 citations

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack , Stephen J. Thomas , Nicholas Kitchin +26 more

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral...

2020 New England Journal of Medicine 14917 citations

Characteristics of SARS-CoV-2 and COVID-19

Ben Hu , Hua Guo , Peng Zhou +1 more

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute re...

2020 Nature Reviews Microbiology 5269 citations

Publication Info

Year: 2020
Type: article
Volume: 384
Issue: 3
Pages: 238-251
Citations: 1763
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1763

OpenAlex

Influential

1527

CrossRef

Cite This

APA Style

                            
                                
                                    David M. Weinreich, 
                                
                                    Sumathi Sivapalasingam, 
                                
                                    Thomas Norton
                                
                                et al.
                            
                            (2020). 
                            REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. 
                            New England Journal of Medicine
                            , 384
                            (3)
                            , 238-251.
                            https://doi.org/10.1056/nejmoa2035002
                        

Identifiers

DOI: 10.1056/nejmoa2035002
PMID: 33332778
PMCID: PMC7781102

Data Quality

Data completeness: 90%